Supplements · Metabolic & Cardiometabolic
quercetin decreases blood pressure
In plain terms: Does quercetin lower your blood pressure?
Leans support Supplements 🔬 Includes disconfirming
Part of: 🧪 quercetin
RefutedContestedStrong support
consensus score 0.45
A little, if yours is already high and you take enough. Pooled trials show about 3 points systolic, but only at 500 mg a day or more, and healthy people with normal blood pressure got no benefit at any dose tested.
📅 Last reviewed: 2026-07-26 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 4 contradict 0 tested null 5 mixed · 18 sources, 13 independent groups
What the evidence shows
Real, small, and conditional on dose and on who you are. Two rigorous human meta-analyses (587 and 896 participants) agree on roughly -3 mmHg systolic and -2.6 to -2.9 mmHg diastolic. Crucially, one reports a DOSE THRESHOLD: significant only at 500 mg/day or above, null below it.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Huang H et al 2020 · Nutrition reviews | meta-analysis | supports | high | Meta-analysis of 17 RCTs (n=896) found quercetin lowered SBP by -3.09 mmHg (95% CI -4.59,-1.59; P=0.0001) and DBP by -2.86 mmHg (95% CI -5.09,-0.63; P=0.01). Lipid changes (HDL, TG) were significant only in parallel-design trials with >=8 w |
| Edwards RL et al 2007 · The Journal of nutrition | RCT | mixed | moderate | Randomized crossover trial of 730 mg/d quercetin for 28 days found no BP change in prehypertensive subjects (n=19) but significant reductions in stage-1 hypertensive subjects (n=22): SBP -7, DBP -5, MAP -5 mmHg (all P<0.01), with no change |
| Zielińska D et al 2025 · study_type: in-vitro | in-vitro | supports | low | In vitro biochemical assay found quercetin was the most potent ACE inhibitor among rutin/quercetin-glucoside derivatives tested (ranking Q > Q3,4'G > Ru > Q3G > Q4'G), with ACE-inhibitory activity correlating with antioxidant potential (r=- |
| Mkhize SA et al 2025 · study_type: animal | animal | supports | low | In L-NAME-induced hypertensive female rats, acute intravenous quercetin (4.5 mg/kg) decreased BP and improved aortic pulse-wave velocity and renal/mesenteric vascular reactivity versus the L-NAME-only state; acute IV dosing in rats, not ora |
| Egert S et al 2009 · The British journal of nutrition | RCT | supports | moderate | Same 6-week crossover RCT (150 mg/d quercetin, n=93 overweight/obese with metabolic-syndrome traits) found SBP fell 2.6 mmHg in the entire group (P<0.01), 2.9 mmHg in the hypertensive subgroup, and 3.7 mmHg in younger adults (25-50y); no si |
| Tamtaji OR et al 2019 · Current pharmaceutical design | meta-analysis | mixed | moderate | Meta-analysis of 8 RCTs in metabolic-syndrome/related-disorder patients found a significant SBP reduction (WMD -1.69 mmHg; 95% CI -3.22,-0.17) but no significant DBP change (WMD -3.14 mmHg; 95% CI -8.24,1.95), and no significant effect on V |
| Silva-Cunha M et al 2026 · study_type: animal | animal | mixed | low | In spontaneously hypertensive rats, oral quercetin (10 mg/kg) alone did not independently lower blood pressure, but it converted a subthreshold, non-antihypertensive nitrite dose (1 mg/kg) into an effective antihypertensive treatment via en |
| Popiolek-Kalisz J et al 2022 · study_type: meta-analysis | meta-analysis | supports | high | Meta-analysis of 10 RCTs (n=841) found quercetin significantly lowered SBP overall (MD -2.38 mmHg, 95% CI -3.80 to -0.96, P=0.01) and in normotensives (MD -1.82 mmHg), and lowered DBP only in the (pre)hypertensive subgroup (MD -3.14 mmHg, 9 |
| Bondonno NP et al 2016 · The American journal of clinical nutrition | RCT | contradicts | moderate | Randomized crossover trial in 15 healthy volunteers given single acute doses of 50-400 mg quercetin-3-O-glucoside found no significant change in BP or endothelial function at any dose 60 min post-dose, despite dose-dependent increases in pl |
| Sivasubramanian MK et al 2026 · study_type: animal | animal | contradicts | low | In high-fat-diet obese mice, combined senolytic dasatinib+quercetin (5+50 mg/kg) improved cardiac autonomic balance (heart-rate variability) versus HFD controls but did not alter radiotelemetry-measured blood pressure or global sympathetic |
| Arabi SM et al 2023 · study_type: meta-analysis | meta-analysis | mixed | moderate | Umbrella review of 5 meta-analyses (18 RCTs) plus 5 additional RCTs found quercetin significantly reduced SBP (WMD -1.9 mmHg, 95% CI -3.2 to -0.6, I2=88.3%) and insulin, but had no significant effect on DBP, lipids, inflammation, or glucose |
| Serban MC et al 2016 · Journal of the American Heart Association | meta-analysis | supports | high | Meta-analysis of 7 RCTs/9 arms (n=587) found quercetin significantly reduced SBP (WMD -3.04 mmHg, P=0.028) and DBP (WMD -2.63 mmHg, P<0.001) overall. Dose-stratified analysis: effect significant at doses >=500 mg/d (SBP -4.45, DBP -2.98 mmH |
| Chopyak VV et al 2025 · study_type: observational | observational | supports | low | Comparative study of 120 stage-II hypertension patients (randomization not stated) found quercetin (Corvitin) added to Ramipril/Amlodipine gave 'more pronounced' improvement in 24-hour BP-monitoring indices and dipper profile than standard |
| Mori A et al 2026 · study_type: animal | animal | contradicts | moderate | In rats, intravenous quercetin (10-100 ug/kg/min) dose-dependently dilated retinal arterioles via a nitric-oxide mechanism, but systemic IV infusion caused no significant change in systemic blood pressure or heart rate. |
| Sagi SSK et al 2026 · study_type: RCT | RCT | supports | moderate | Double-blind RCT in 110 healthy lowlanders given 500 mg/day quercetin (bar) vs placebo for 15 days during high-altitude ascent found both SBP (-8 mmHg) and DBP (-4 mmHg) significantly lower in the quercetin group (p<0.001), alongside reduce |
| Mantadaki AE et al 2024 · study_type: RCT | RCT | contradicts | low | Interim analysis (38 of 100 enrolled) of an RCT in T2DM patients given 500 mg/d quercetin for 12 weeks found a numerically greater SBP drop than control (-7.4% vs -3.7%) that did not reach significance (P=0.117); the trial's significant fin |
| Egert S et al 2010 · The Journal of nutrition | RCT | mixed | moderate | In a 6-week crossover RCT (150 mg/d quercetin) in 93 overweight/obese adults with metabolic-syndrome traits stratified by apoE genotype, SBP fell 3.4 mmHg (P<0.01) in apoE3 carriers (n=60) but showed no significant BP effect in apoE4 carrie |
| Mantadaki AE et al 2024 · study_type: RCT | RCT | supports | moderate | Open-label RCT in 88 completing T2DM patients given 500 mg/day quercetin for 12 weeks (with an 8-week washout then a repeat 12-week course) found SBP fell -5.0% vs -0.2% in controls (p=0.029), alongside improved HbA1c, FEV1, sleep and anxie |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.